EPIDEMIOLOGY OF CAROTID ARTERY DISEASE IN OLDER ADULTS

老年人颈动脉疾病的流行病学

• 批准号: 6183380
• 负责人: KIM SUTTON TYRRELL
• 金额: $ 28.51万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6183380
• 关键词: aging; antihypertensive agents; atherosclerosis; blood chemistry; calcification; cardiovascular disorder chemotherapy; cardiovascular disorder epidemiology; carotid artery; cognition; computed axial tomography; disease /disorder etiology; disease /disorder proneness /risk; human old age (65+); human subject; human therapy evaluation; hypertension; interview; pathologic process; placebos; ultrasound blood flow measurement

DESCRIPTION: (Adapted from Investigator's Abstract) This is an ancillary study to the Systolic Hypertension in the Elderly Program (SHEP). It presents plans for investigating the prevalence and prognostic value of subclinical atherosclerosis in the Pittsburgh SHEP cohort and a cohort of normotensive controls. Continued annual telephone follow-up of the remaining 178 SHEP participants and 168 controls is proposed. A final clinic visit will include measures of coronary and aortic calcification using electron beam computed tomography (CT), pulse wave velocity as a measure of aortic stiffening and cognitive function testing. For the Pittsburgh SHEP cohort, the antihypertensive treatment effect has been striking with event rates for the active and placebo groups continuing to diverge beyond the end of SHEP. Successful demonstration of a treatment effect on coronary calcium scores would be the first randomized data showing an antihypertensive effect directly in the coronary arteries. Risk factors for coronary calcification will be evaluated, producing data of a type not yet available in the literature for older adults and not being collected in any other ongoing studies of the elderly. The added measures of vascular stiffness will supplement the extensive data on subclinical atherosclerosis already available for this cohort. The extent to which these measures predict cardiovascular events will be evaluated. Since hypertension and aging are associated with cognitive impairment and vascular dementia, SHEP participants assigned to the placebo group are expected to have lower cognitive function compared to those assigned to active treatment. Among both hypertensive and normotensive groups, lower cognitive function among those with evidence of subclinical atherosclerosis is expected. Finally, members of the cohort who were originally normotensive at study entry are now developing systolic hypertension. These subjects will allow a prospective evaluation of risk factors for systolic hypertension. Continued study of this cohort into their 80s will provide unique data on the risks and etiology of systolic hypertension, the efficacy of its treatment and the prognostic value of a number of measures of subclinical atherosclerosis. It is predicted that the results will be directly applicable to the largest growing segment of the U.S. population.

描述：（根据调查员的摘要改编）这是一个辅助 研究老年人计划（SHEP）中的收缩期高血压。 它 提出了调查的计划 匹兹堡Shep队列中的亚临床动脉粥样硬化和一群 正常的控制。 持续的年度电话随访 提出了其余178名SHEP参与者和168个对照。 决赛 诊所就诊将包括冠状动脉和主动脉钙化的措施 使用电子束计算机断层扫描（CT），脉冲波速度作为一个 主动脉僵硬和认知功能测试的度量。 为了 匹兹堡Shep队列，降压治疗效果一直是 对活动和安慰剂组的事件率的震撼 脱离了Shep的尽头。 成功证明治疗 对冠状钙评分的影响将是第一个显示的随机数据 直接在冠状动脉中的降压作用。 风险因素 将评估冠状动脉钙化，生成类型的数据 在文献中可用于老年人，但没有收集 任何其他对老年人的研究。 血管的添加措施 刚度将补充亚临床动脉粥样硬化的广泛数据 已经可用于此队列。 这些措施的程度 将评估预测心血管事件。 由于高血压和衰老与认知障碍和 分配给安慰剂组的血管痴呆，SHEP参与者是 预计与分配给的认知功能较低 主动治疗。 在高血压和正常的群体中，较低 具有亚临床动脉粥样硬化证据的人的认知功能 预期。 最后，最初在研究方面正常引人注目的队列成员 现在正在发展收缩期高血压。 这些主题将允许 预期评估收缩期高血压的危险因素。 持续 将此队列研究到80年代将提供有关风险的独特数据 和收缩压的病因，其治疗的功效及 亚临床动脉粥样硬化的多种测量值的预后价值。 它 预测结果将直接适用于最大的 不断增长的美国人口。